Share this post on:

Product Name :
Ruzinurad

Search keywords :
Ruzinurad

drugId :
null

Target Vo:
Uric acid transporter 1

Target Vo Short Name :
URAT1

Moa_Name:
Uric acid transporter 1 inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Jiangsu Hengrui Medicine Co Ltd

Active Company_Name :
Jiangsu Hengrui Medicine Co Ltd

Active Indication_Name:
Hyperuricemia

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 3 Clinical

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Lemzoparlimab Immunology/Inflammation
RhoA Rabbit pAb Autophagy
TGF beta Receptor II Antibody: TGF beta Receptor II Antibody is an unconjugated, approximately 62 kDa, rabbit-derived, anti-TGF beta Receptor II polyclonal antibody. TGF beta Receptor II Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, cow, and predicted: chicken, pig, horse, rabbit, sheep background without labeling.

Share this post on:

Author: Interleukin Related